<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196921</url>
  </required_header>
  <id_info>
    <org_study_id>MB-70009</org_study_id>
    <nct_id>NCT03196921</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection</brief_title>
  <acronym>ORACLE</acronym>
  <official_title>A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas BioPharma Nanotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Matinas BioPharma Nanotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open label phase I/II prospective cohort study to determine the efficacy and
      safety of CAMB for the treatment and prevention of cryptococcal infection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Patients with symptomatic cryptococcal meningitis will be enrolled in treatment arm Patients that are CRAG positive will be enrolled the in prevention arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of drug over 14 days of dosing</measure>
    <time_frame>14-days</time_frame>
    <description>Tolerability of drug as measured by the proportion of doses received versus the number of scheduled doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiologic clearance of Cryptococcus from the CSF</measure>
    <time_frame>14-days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>14-days</time_frame>
    <description>stratified by symptomatic and asymptomatic subgroups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival from cryptococcal infection</measure>
    <time_frame>10-weeks</time_frame>
    <description>stratified by symptomatic and asymptomatic subgroups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>24-hours</time_frame>
    <description>PK parameter of Area Under the Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>24-hours</time_frame>
    <description>PK parameter of the maximum concentration (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cryptococcal Infections</condition>
  <arm_group>
    <arm_group_label>Symptomatic Cryptococcal Meningitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAMB (Encochleated Amphotericin B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic Cryptococcal Antigenemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAMB (Encochleated Amphotericin B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encochleated Amphotericin B</intervention_name>
    <description>lipid-crystal nanoparticle formulation of amphotericin B; oral</description>
    <arm_group_label>Symptomatic Cryptococcal Meningitis</arm_group_label>
    <arm_group_label>Asymptomatic Cryptococcal Antigenemia</arm_group_label>
    <other_name>CAMB</other_name>
    <other_name>MAT2203</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection, informed consent, cryptococcal infection present, diagnosed by either:
             CSF cryptococcal culture, CSF cryptococcal antigen (CRAG), plasma/serum CRAG

        Exclusion Criteria:

          -  Presence of jaundice or known liver cirrhosis, &gt;72 hours antifungal therapy, pregnancy
             or breastfeeding, unlikely to attend regular clinic visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Boulware, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tafese Beyene Tufa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asella Teaching Hospital, Arsi University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Douglas Kling</last_name>
    <phone>(908) 505-0964</phone>
    <email>dkling@matinasbiopharma.com</email>
  </overall_contact>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amphotericin B</keyword>
  <keyword>cryptococcal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

